Announced
Tong Ren Tang to acquire CLSA Premium for HKD250m.
Synopsis
Tong Ren Tang, a Chinese pharmaceutical company, agreed to acquire CLSA Premium, an investment holding company selling healthcare products and other services, for HKD250m.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
All rights reserved. Copyright © 2025 Datasite